BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
Covington
UBS
Mallinckrodt
Deloitte
Fuji
McKesson
QuintilesIMS
Healthtrust

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,149,938

« Back to Dashboard

Which drugs does patent 6,149,938 protect, and when does it expire?

Patent 6,149,938 protects SUPRENZA and is included in one NDA.

This patent has nine patent family members in ten countries.
Summary for Patent: 6,149,938
Title: Process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets and compositions obtained thereby
Abstract:A process for making a granulate composition suitable to the preparation of an oral solid form that can disintegrate rapidly inside the buccal cavity is provided as well as the granulate compositions and obtained.
Inventor(s): Bonadeo; Daniele (Varese, IT), Ciccarello; Franco (Via la Loggia Mezzovico, CH), Pagano; Aberto (L'Aquila, IT)
Assignee: Elan Pharma International Limited (Dublin, IE)
Application Number:09/122,037
Patent Claim Types:
see list of patent claims
Dosage form; Process; Composition; Formulation;

Drugs Protected by US Patent 6,149,938

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-001 Jun 13, 2011 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-002 Jun 13, 2011 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-003 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe Y WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,149,938

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1797/97Jul 25, 1997

International Patents Family Members for US Patent 6,149,938

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2298487 ➤ Subscribe
Germany 69834255 ➤ Subscribe
Denmark 1001748 ➤ Subscribe
European Patent Office 1001748 ➤ Subscribe
Spain 2263216 ➤ Subscribe
Japan 2001510785 ➤ Subscribe
Australia 8977698 ➤ Subscribe
Austria 323467 ➤ Subscribe
Japan 4947833 ➤ Subscribe
Portugal 1001748 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
AstraZeneca
Colorcon
Chinese Patent Office
US Army
Fish and Richardson
Cipla
Dow
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot